– SWITZERLAND, Basel – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, announced the appointment of John Schmid to its Board of Directors, bringing more than 35 years of financial and senior management experience in the biotechnology industry.
“It is a pleasure to welcome John to our Board,” said CEO Fredrik Wiklund. “John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term success.”
About John Schmid
As CFO, John Schmid has raised over $900 million through private and public equity and debt financings. He has guided two companies through successful IPOs as a CFO, and over the course of the last ten years, he has been involved in six additional IPOs as an independent board member.
John Schmid serves on the Boards of AnaptysBio (Nasdaq: ANAB), Design Therapeutics (Nasdaq: DSGN), Poseida Therapeutics (Nasdaq: PSTX), and Xeris Pharmaceuticals (Nasdaq: XERS), as well as the SPAC Helix Acquisition (Nasdaq: HLXA), acting as Audit Chair for each. He is also a Board Member of Forge Therapeutics and Speak, Inc.
Previously, John Schmid was CFO of Auspex Pharmaceuticals, which he took public in 2014 and later sold to Teva for $3.5 billion. He also co-founded Trius Therapeutics in 2004, serving as CFO through its IPO and eventual acquisition by Cubist Pharmaceuticals for over $700 million. Before Trius, he was CFO of GeneFormatics and Endonetics as well as an Associate with Idanta Partners, a venture capital firm, VP at HomeFed Bank, and a Financial Analyst for Manufacturers Hanover (now part of J.P. Morgan) in New York. He is a past President and a past board member of the San Diego Venture Group.
“I’m honored to join Bright Peak as an Independent Board Member,” said Mr. Schmid. “I look forward to collaborating with the leadership team and fellow Directors in support of the company’s mission of advancing breakthrough immunotherapies to patients with cancer.”
John Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.
About Bright Peak Therapeutics
Bright Peak Therapeutics is a clinical-stage biotechnology company pioneering multifunctional immunotherapies to treat cancer. Leveraging innovative protein engineering and a proprietary chemical conjugation platform, Bright Peak is building a robust pipeline of first-in-class multifunctional molecules. Its lead program, BPT567—a bifunctional PD1-IL18 immunoconjugate—is currently in Phase 1/2a clinical trials. Backed by leading healthcare investors, Bright Peak operates from its dual locations in San Diego, CA, and Basel, Switzerland.
For more: https://brightpeaktx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.